We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANI Pharmaceuticals (ANIP - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ANI Pharmaceuticals is one of 1000 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ANI Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for ANIP's full-year earnings has moved 23.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ANIP has moved about 24.7% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.6%. As we can see, ANI Pharmaceuticals is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Agenus (AGEN - Free Report) . The stock has returned 4.7% year-to-date.
For Agenus, the consensus EPS estimate for the current year has increased 30.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 508 individual companies and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have lost 6.5% this year, meaning that ANIP is performing better in terms of year-to-date returns. Agenus is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on ANI Pharmaceuticals and Agenus as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANI Pharmaceuticals (ANIP - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ANI Pharmaceuticals is one of 1000 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ANI Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for ANIP's full-year earnings has moved 23.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ANIP has moved about 24.7% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.6%. As we can see, ANI Pharmaceuticals is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Agenus (AGEN - Free Report) . The stock has returned 4.7% year-to-date.
For Agenus, the consensus EPS estimate for the current year has increased 30.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 508 individual companies and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have lost 6.5% this year, meaning that ANIP is performing better in terms of year-to-date returns. Agenus is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on ANI Pharmaceuticals and Agenus as they attempt to continue their solid performance.